State Street’s Biocept, Inc. BIOC Stock Holding History

State Street’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,353	Closed	-$13.8K	–	4803
2023 Q1	$13.8K	Hold	1,353	–	–	﹤0.01%	4723
2022 Q4	$21.5K	Hold	1,353	–	–	﹤0.01%	4723
2022 Q3	$37K	Hold	1,353	–	–	﹤0.01%	4723
2022 Q2	$38K	Buy	1,353 +66	+5%	+$3.01K	﹤0.01%	4781
2022 Q1	$90K	Hold	1,287	–	–	﹤0.01%	4674
2021 Q4	$140K	Hold	1,287	–	–	﹤0.01%	4489
2021 Q3	$155K	Buy	1,287 +20	+2%	+$2.33K	﹤0.01%	4438
2021 Q2	$159K	Buy	+1,267	New	+$171K	﹤0.01%	4268
2018 Q3	–	Sell	-1	Closed	-$2K	–	3813
2018 Q2	$2K	Hold	1	–	–	﹤0.01%	3768
2018 Q1	$3K	Hold	1	–	–	﹤0.01%	3750
2017 Q4	$7K	Hold	1	–	–	﹤0.01%	3722
2017 Q3	$12K	Hold	1	–	–	﹤0.01%	3738
2017 Q2	$14K	Hold	1	–	–	﹤0.01%	3671
2017 Q1	$21K	Buy	+1	New	+$17K	﹤0.01%	3616

Other funds holding BIOC

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street's BIOC Position: Q2 2023 in Review

State Street sold out of Biocept, Inc. (BIOC) in Q2 2023, closing a stake of 1,353 shares — an estimated $13.8K sold.

State Street first reported a position in BIOC in Q1 2017 and held it in 14 quarters. The position peaked at $159K in Q2 2021. 11 funds tracked by Wall St. Rank hold BIOC as of Q2 2023.

State Street reported no remaining Biocept, Inc. position as of Q2 2023 after selling out during the quarter.
State Street sold 1,353 Biocept, Inc. shares in Q2 2023, an estimated $13.8K.
State Street first reported a position in Biocept, Inc. in Q1 2017 and held it in 14 quarters.
State Street's Biocept, Inc. position peaked at $159K in Q2 2021.
11 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2023.

Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.